

Supplemental References

1. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science*. 2008 Sep 26;321(5897):1801-6.
2. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. *Genes Dev*. 2006 May 1;20(9):1123-36.
3. McGarvey KM, Van Neste L, Cope L, Ohm JE, Herman JG, Van Criekinge W, et al. Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. *Cancer Res*. 2008 Jul 15;68(14):5753-9.
4. Ringrose L. Polycomb comes of age: genome-wide profiling of target sites. *Curr Opin Cell Biol*. 2007 Jun;19(3):290-7.
5. Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. *Cancer Res*. 2006 Jun 15;66(12):6080-6.
6. Habano W, Gamo T, Sugai T, Otsuka K, Wakabayashi G, Ozawa S. CYP1B1, but not CYP1A1, is downregulated by promoter methylation in colorectal cancers. *Int J Oncol*. 2009 Apr;34(4):1085-91.
7. Dietrich D, Lesche R, Tetzner R, Krispin M, Dietrich J, Haedicke W, et al. Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues. *J Histochem Cytochem*. 2009 May;57(5):477-89.
8. Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, Solomon A, et al. Characterizing DNA methylation patterns in pancreatic cancer genome. *Mol Oncol*. 2009 Dec;3(5-6):425-38.
9. Vanaja DK, Ehrich M, Van den Boom D, Chevillat JC, Karnes RJ, Tindall DJ, et al. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. *Cancer Invest*. 2009 Jun;27(5):549-60.
10. Ishikawa J, Taniguchi T, Takeshita A, Maekawa M. Increased creatine kinase BB activity and CKB mRNA expression in patients with hematologic disorders: relation to methylation status of the CKB promoter. *Clin Chim Acta*. 2005 Nov;361(1-2):135-40.
11. Omura N, Li CP, Li A, Hong SM, Walter K, Jimeno A, et al. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. *Cancer Biol Ther*. 2008 Jul;7(7):1146-56.
12. Rauch T, Li H, Wu X, Pfeifer GP. MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. *Cancer Res*. 2006 Aug 15;66(16):7939-47.
13. Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, et al. CpG island hypermethylation in human astrocytomas. *Cancer Res*. Apr 1;70(7):2718-27.
14. Ogishima T, Shiina H, Breault JE, Terashima M, Honda S, Enokida H, et al. Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. *Oncogene*. 2005 Oct 13;24(45):6765-72.

15. Kumagai T, Akagi T, Desmond JC, Kawamata N, Gery S, Imai Y, et al. Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. *Int J Cancer*. 2009 Feb 15;124(4):827-33.
16. Jin B, Yao B, Li JL, Fields CR, Delmas AL, Liu C, et al. DNMT1 and DNMT3B modulate distinct polycomb-mediated histone modifications in colon cancer. *Cancer Res*. 2009 Sep 15;69(18):7412-21.
17. Miyamoto K, Fukutomi T, Akashi-Tanaka S, Hasegawa T, Asahara T, Sugimura T, et al. Identification of 20 genes aberrantly methylated in human breast cancers. *Int J Cancer*. 2005 Sep 1;116(3):407-14.
18. Rauch TA, Zhong X, Wu X, Wang M, Kernstine KH, Wang Z, et al. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. *Proc Natl Acad Sci U S A*. 2008 Jan 8;105(1):252-7.
19. Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. *Leukemia*. 2008 Aug;22(8):1529-38.
20. Dahl E, Wiesmann F, Woenckhaus M, Stoehr R, Wild PJ, Veeck J, et al. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. *Oncogene*. 2007 Aug 16;26(38):5680-91.
21. Miotto E, Sabbioni S, Veronese A, Calin GA, Gullini S, Liboni A, et al. Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. *Cancer Res*. 2004 Nov 15;64(22):8156-9.
22. Kusakabe M, Kutomi T, Watanabe K, Emoto N, Aki N, Kage H, et al. Identification of G0S2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches. *Int J Cancer*. Apr 15;126(8):1895-902.
23. Ulazzi L, Sabbioni S, Miotto E, Veronese A, Angusti A, Gafa R, et al. Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. *Mol Cancer*. 2007;6:17.
24. Chen WD, Han ZJ, Skoletsy J, Olson J, Sah J, Myeroff L, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. *J Natl Cancer Inst*. 2005 Aug 3;97(15):1124-32.
25. Cho CY, Wang JH, Chang HC, Chang CK, Hung WC. Epigenetic inactivation of the metastasis suppressor RECK enhances invasion of human colon cancer cells. *J Cell Physiol*. 2007 Oct;213(1):65-9.
26. Hong SM, Kelly D, Griffith M, Omura N, Li A, Li CP, et al. Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. *Mod Pathol*. 2008 Dec;21(12):1499-507.
27. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. *Cancer Res*. 2003;63(13):3735-42.
28. Feng Q, Hawes SE, Stern JE, Wiens L, Lu H, Dong ZM, et al. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. *Cancer Epidemiol Biomarkers Prev*. 2008 Mar;17(3):645-54.
29. Tsutsui M, Iizuka N, Moribe T, Miura T, Kimura N, Tamatsukuri S, et al. Methylated cyclin D2 gene circulating in the blood as a prognosis predictor of hepatocellular carcinoma. *Clin Chim Acta*. Apr 2;411(7-8):516-20.

30. Suzuki M, Shigematsu H, Shames DS, Sunaga N, Takahashi T, Shivapurkar N, et al. DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. *Br J Cancer*. 2005 Oct 31;93(9):1029-37.
31. Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, et al. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. *Cancer Epidemiol Biomarkers Prev*. 2006 Jan;15(1):114-23.
32. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, et al. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. *Epigenetics*. Aug 27;5(6).
33. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. *Cancer Res*. 2003 Nov 15;63(22):7641-5.
34. Ying J, Li H, Yu J, Ng KM, Poon FF, Wong SC, et al. WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. *Clin Cancer Res*. 2008 Jan 1;14(1):55-61.
35. Hartmann O, Spyrtos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M, et al. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. *Clin Cancer Res*. 2009 Jan 1;15(1):315-23.
36. Estecio MR, Yan PS, Ibrahim AE, Tellez CS, Shen L, Huang TH, et al. High-throughput methylation profiling by MCA coupled to CpG island microarray. *Genome Res*. 2007 Oct;17(10):1529-36.
37. Gao W, Kondo Y, Shen L, Shimizu Y, Sano T, Yamao K, et al. Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. *Carcinogenesis*. 2008 Oct;29(10):1901-10.
38. Takada H, Imoto I, Tsuda H, Nakanishi Y, Sakakura C, Mitsufuji S, et al. Genomic loss and epigenetic silencing of very-low-density lipoprotein receptor involved in gastric carcinogenesis. *Oncogene*. 2006 Oct 19;25(49):6554-62.
39. Cecconi D, Astner H, Donadelli M, Palmieri M, Missiaglia E, Hamdan M, et al. Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2'-deoxycytidine. *Electrophoresis*. 2003 Dec;24(24):4291-303.
40. Ikeda JI, Morii E, Kimura H, Tomita Y, Takakuwa T, Hasegawa JI, et al. Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells. *J Pathol*. 2006 Sep;210(1):75-84.
41. Guo Z, Chen Z, Yang Z, Schumaker L, Trink B, Cullen K. Discovery of the genes silenced by promoter hypermethylation in cisplatin resistance of ovarian cancer. *AACR*; 2006; 2006.
42. Guo Z, Yang Z, Chen Z, Schumaker L, Califano J, Cullen K. Genomewide search of novel hypermethylated genes associated with cisplatin resistance in head and neck cancer *Proc Amer Assoc Cancer Res*. 2006;47.
43. Bernert H, Brait M, Ostrow K, Loyo M, Dasgupta S, Sidransky D, et al. Promoter hypermethylation of candidate tumor suppressor genes in bladder and prostate cancer. *Proc Amer Assoc Cancer Res*. 2008;42.

44. Misawa K, Ueda Y, Kanazawa T, Misawa Y, Jang I, Brenner JC, et al. Epigenetic inactivation of galanin receptor 1 in head and neck cancer. *Clin Cancer Res.* 2008 Dec 1;14(23):7604-13.
45. Korshunova Y, Maloney RK, Lakey N, Citek RW, Bacher B, Budiman A, et al. Massively parallel bisulphite pyrosequencing reveals the molecular complexity of breast cancer-associated cytosine-methylation patterns obtained from tissue and serum DNA. *Genome Res.* 2008 Jan;18(1):19-29.
46. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. *Blood.* 2001 May 1;97(9):2823-9.
47. Huang Y, Deatherage D, Yan P, Mallon MA, Miller D, Mutch DG, et al. Hypermethylation of CIDEA and RXFP3 as potential epigenetic markers for endometrial cancer. *Proc Amer Assoc Cancer Res.* 2008;50.
48. Cottrell S, Jung K, Kristiansen G, Eltze E, Semjonow A, Ittmann M, et al. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. *J Urol.* 2007 May;177(5):1753-8.
49. Figueroa ME, Wouters BJ, Skrabanek L, Glass J, Li Y, Erpelinck-Verschueren CA, et al. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. *Blood.* 2009 Mar 19;113(12):2795-804.
50. Yu YP, Paranjpe S, Nelson J, Finkelstein S, Ren B, Kokkinakis D, et al. High throughput screening of methylation status of genes in prostate cancer using an oligonucleotide methylation array. *Carcinogenesis.* 2005 Feb;26(2):471-9.
51. Tong WG, Wierda WG, Bekele N, Kuang SQ, Keating MJ, Garcia-Manero G. Genome-Wide DNA Methylation Profile of CLL with 17p del Allowed Identification of Multiple Epigenetically Inactivated Molecular Pathways with Prognostic Value in Human Leukemia. *Blood (ASH Annual Meeting Abstracts);* 2007; 2007.
52. Model F, Osborn N, Ahlquist D, Gruetzmann R, Molnar B, Sipos F, et al. Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease. *Mol Cancer Res.* 2007 Feb;5(2):153-63.
53. Taylor KH, Kramer RS, Davis JW, Guo J, Duff DJ, Xu D, et al. Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. *Cancer Res.* 2007 Sep 15;67(18):8511-8.
54. Gasco M, Syed N, Coley H, Colantonio I, Merlano M, Crook T, et al. Novel genes mediating cisplatin resistance in head and neck cancer. *Journal of Clinical Oncology;* 2009; 2009.
55. Kuang SQ, Yang H, Jelinek J, Tong W, Issa JP, Garcia-Manero G. Identification of novel differentially methylated markers in adult acute lymphocytic leukemias. 2007; 2007.
56. Ueki T, Toyota M, Skinner H, Walter KM, Yeo CJ, Issa JP, et al. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. *Cancer Res.* 2001 Dec 1;61(23):8540-6.
57. Roll JD, Rinkenbaugh AL, Sandhu R, Rivenbark AG, Coleman WB. RNAi-Mediated Knockdown of DNMT3b in Hypermethylator Breast Cancer Cell Lines Leads to Normalization of Gene Expression Patterns. 2009; 2009.

58. Nishigaki M, Aoyagi K, Danjoh I, Fukaya M, Yanagihara K, Sakamoto H, et al. Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. *Cancer Res.* 2005 Mar 15;65(6):2115-24.
59. Gray SG, Cathcart MC, Al-Sarraf N, G.P. P, O'Byrne KJ. Prostacyclin synthase (PTGIS) expression and epigenetic regulation in non-small cell lung cancer (NSCLC). ASCO Meeting; 2009; 2009.
60. deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. *Clin Chem.* 2009 Jul;55(7):1337-46.
61. Costello JF, Plass C. Methylation matters. *J Med Genet.* 2001 May;38(5):285-303.
62. Zou H, Harrington JJ, Shire AM, Rego RL, Wang L, Campbell ME, et al. Highly methylated genes in colorectal neoplasia: implications for screening. *Cancer Epidemiol Biomarkers Prev.* 2007 Dec;16(12):2686-96.
63. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A, et al. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. *PLoS One.* 2009;4(3):e4830.
64. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. *Science.* 2003 Mar 14;299(5613):1753-5.
65. Karpinski P, Ramsey D, Grzebieniak Z, Sasiadek MM, Blin N. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer. *Mol Cancer Res.* 2008 Apr;6(4):585-91.
66. Hahn MA, Hahn T, Lee DH, Esworthy RS, Kim BW, Riggs AD, et al. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. *Cancer Res.* 2008 Dec 15;68(24):10280-9.
67. Mori Y, Cheng Y, Olaru A, Paun B, Jin Z, Sato F, et al. The PKC binding protein gene NELL1 and the T-cell differentiation protein gene MAL are hypermethylated in gastric cancer. AACR Meeting; 2007; 2007.
68. Sepulveda AR, Jones D, Ogino S, Samowitz W, Gulley ML, Edwards R, et al. CpG methylation analysis--current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. *J Mol Diagn.* 2009 Jul;11(4):266-78.
69. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. *Cancer Res.* 2000 Apr 1;60(7):1835-9.
70. Akiyama Y, Wanajo A, Otsubo T, Nagasaki H, Yuasa Y. Promoter hypermethylation of the calcium channel-related gene, CACNA2D3, is frequent and an independently poor prognostic factor in gastric carcinomas. AACR Meeting; 2008; 2008.
71. Yamada Y, Toyota M, Hirokawa Y, Suzuki H, Takagi A, Matsuzaki T, et al. Identification of differentially methylated CpG islands in prostate cancer. *Int J Cancer.* 2004 Dec 10;112(5):840-5.
72. Wang Y, Yu Q, Cho AH, Rondeau G, Welsh J, Adamson E, et al. Survey of differentially methylated promoters in prostate cancer cell lines. *Neoplasia.* 2005 Aug;7(8):748-60.

73. Trojan J, Brieger A, Raedle J, Esteller M, Zeuzem S. 5'-CpG island methylation of the LKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorectal cancer. *Gut*. 2000 Aug;47(2):272-6.
74. Ehrlich M, Turner J, Gibbs P, Lipton L, Giovanneti M, Cantor C, et al. Cytosine methylation profiling of cancer cell lines. *Proc Natl Acad Sci U S A*. 2008 Mar 25;105(12):4844-9.
75. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. *Proc Natl Acad Sci U S A*. 2009 Jun 9;106(23):9435-40.
76. Anglim PP, Galler JS, Koss MN, Hagen JA, Turla S, Campan M, et al. Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. *Mol Cancer*. 2008;7:62.
77. Wimmer K, Zhu Xx XX, Rouillard JM, Ambros PF, Lamb BJ, Kuick R, et al. Combined restriction landmark genomic scanning and virtual genome scans identify a novel human homeobox gene, ALX3, that is hypermethylated in neuroblastoma. *Genes Chromosomes Cancer*. 2002 Mar;33(3):285-94.
78. Yu J, Zhu T, Wang Z, Zhang H, Qian Z, Xu H, et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. *Clin Cancer Res*. 2007 Dec 15;13(24):7296-304.
79. Tessema M, Yu YY, Stidley CA, Machida EO, Schuebel KE, Baylin SB, et al. Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. *Carcinogenesis*. 2009 Jul;30(7):1132-8.
80. Phillips JM, Goodman JJ. Multiple genes exhibit phenobarbital-induced constitutive active/androstane receptor-mediated DNA methylation changes during liver tumorigenesis and in liver tumors. *Toxicol Sci*. 2009 Apr;108(2):273-89.
81. Kochetkova M, McKenzie OL, Bais AJ, Martin JM, Secker GA, Seshadri R, et al. CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3. *Cancer Res*. 2002 Aug 15;62(16):4599-604.
82. Guo M, House MG, Suzuki H, Ye Y, Brock MV, Lu F, et al. Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer. *Int J Cancer*. 2007 Sep 15;121(6):1219-26.
83. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. *Cancer Res*. 2005 May 15;65(10):4218-27.
84. Bennett KL, Karpenko M, Lin MT, Claus R, Arab K, Dyckhoff G, et al. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. *Cancer Res*. 2008 Jun 15;68(12):4494-9.
85. Yasunaga J, Taniguchi Y, Nosaka K, Yoshida M, Satou Y, Sakai T, et al. Identification of aberrantly methylated genes in association with adult T-cell leukemia. *Cancer Res*. 2004 Sep 1;64(17):6002-9.
86. Lo PK, Lee JS, Liang X, Mori T, Mehrotra J, Fackler MJ, et al. The forkhead box-F (FOXF) proteins, important regulators in development, function as tumor suppressors and are epigenetically silenced in breast cancer. *AACR Meeting*; 2007; 2007.

87. Jones PA, Baylin SB. The epigenomics of cancer. *Cell*. 2007 Feb 23;128(4):683-92.
88. Yamashita K, Kim MS, Park HL, Tokumaru Y, Osada M, Inoue H, et al. HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma. *Mol Cancer Res*. 2008 Jan;6(1):31-41.
89. Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ, Hoon DS. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. *Clin Cancer Res*. 2004 Nov 15;10(22):7475-83.
90. Bennett KL, Romigh T, Eng C. Disruption of transforming growth factor-beta signaling by five frequently methylated genes leads to head and neck squamous cell carcinoma pathogenesis. *Cancer Res*. 2009 Dec 15;69(24):9301-5.
91. Ordway JM, Bedell JA, Citek RW, Nunberg A, Garrido A, Kendall R, et al. Comprehensive DNA methylation profiling in a human cancer genome identifies novel epigenetic targets. *Carcinogenesis*. 2006 Dec;27(12):2409-23.
92. Chung W, Kwabi-Addo B, Ittmann aM, Issa JP. Identification of novel hypermethylated genes in primary prostate cancer and colon cancer. *AACR Meeting*; 2006; 2006.
93. Sato N, Fukushima N, Hruban RH, Goggins M. CpG island methylation profile of pancreatic intraepithelial neoplasia. *Mod Pathol*. 2008 Mar;21(3):238-44.
94. Bloushtain-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA, et al. Cell type-specific DNA methylation patterns in the human breast. *Proc Natl Acad Sci U S A*. 2008 Sep 16;105(37):14076-81.
95. Bennett KL, Hackanson B, Smith LT, Morrison CD, Lang JC, Schuller DE, et al. Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. *Cancer Res*. 2007 May 15;67(10):4657-64.
96. Gebhard C, Schwarzfischer L, Pham TH, Schilling E, Klug M, Andreessen R, et al. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. *Cancer Res*. 2006 Jun 15;66(12):6118-28.
97. Fiegl H, Jones A, Hauser-Kronberger C, Hutarew G, Reitsamer R, Jones RL, et al. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. *Clin Cancer Res*. 2008 Jun 1;14(11):3494-502.
98. Taylor KH, Pena-Hernandez KE, Rahmatpanah F, Sjahputera O, Shi H, Caldwell CW. Epigenetic profiling delineates acute lymphoblastic leukemia subtypes and identifies putative tumor suppressor genes. *AACR Meeting*; 2005; 2005.
99. Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. *Cancer Res*. 2006 Nov 1;66(21):10517-24.
100. Zigelboim I, Goodfellow PJ, Schmidt AP, Walls KC, Mallon MA, Mutch DG, et al. Differential methylation hybridization array of endometrial cancers reveals two novel cancer-specific methylation markers. *Clin Cancer Res*. 2007 May 15;13(10):2882-9.
101. Tellez CS, Shen L, Oki Y, Estécio MRH, Gershenwald JE, Issa JP. CpG island hypermethylation profile of human melanoma cell lines in relation to global methylation and mutations in BRAF and NRAS. *AACR Meeting*; 2006; 2006.

102. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. *Cancer Res.* 2003 Jul 1;63(13):3735-42.
103. Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP, Vadgama JV. Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. *Mol Cancer Ther.* Jan;9(1):33-45.
104. Yoshida M, Nosaka K, Yasunaga J, Nishikata I, Morishita K, Matsuoka M. Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells. *Blood.* 2004 Apr 1;103(7):2753-60.
105. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, Lau SK, et al. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. *Proc Natl Acad Sci U S A.* 2007 Mar 27;104(13):5527-32.
106. Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. *Clin Chem.* 2008 Feb;54(2):414-23.
107. Dammann R, Strunnikova M, Schagdarsurengin U, Rastetter M, Papritz M, Hattenhorst UE, et al. CpG island methylation and expression of tumour-associated genes in lung carcinoma. *Eur J Cancer.* 2005 May;41(8):1223-36.
108. Zhang Y, Huang S, Dong W, Li L, Feng Y, Pan L, et al. SOX7, down-regulated in colorectal cancer, induces apoptosis and inhibits proliferation of colorectal cancer cells. *Cancer Lett.* 2009 May 8;277(1):29-37.
109. Wang SS, Smiraglia DJ, Wu YZ, Ghosh S, Rader JS, Cho KR, et al. Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. *Cancer Res.* 2008 Apr 1;68(7):2489-97.
110. Heller G, Schmidt WM, Ziegler B, Holzer S, Mullauer L, Bilban M, et al. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. *Cancer Res.* 2008 Jan 1;68(1):44-54.
111. Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. *Cancer Sci.* 2006 Jan;97(1):64-71.
112. Gu W, Pan F, Singer RH. Blocking beta-catenin binding to the ZBP1 promoter represses ZBP1 expression, leading to increased proliferation and migration of metastatic breast-cancer cells. *J Cell Sci.* 2009 Jun 1;122(Pt 11):1895-905.
113. Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, Weisenberger DJ, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. *Gut.* 2006 Jul;55(7):1000-6.
114. Chen CM, Chen HL, Hsiao TH, Hsiao AH, Shi H, Brock GJ, et al. Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes. *Am J Pathol.* 2003 Jul;163(1):37-45.
115. Wilting SM, Steenbergen RD, Tijssen M, van Wieringen WN, Helmerhorst TJ, van Kemenade FJ, et al. Chromosomal signatures of a subset of high-grade premalignant cervical lesions closely resemble invasive carcinomas. *Cancer Res.* 2009 Jan 15;69(2):647-55.

116. Sato N, Maitra A, Fukushima N, van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. *Cancer Res.* 2003 Jul 15;63(14):4158-66.
117. Novak P, Jensen T, Oshiro MM, Watts GS, Kim CJ, Futscher BW. Agglomerative epigenetic aberrations are a common event in human breast cancer. *Cancer Res.* 2008 Oct 15;68(20):8616-25.
118. Ghosh S, Ghosh A, Maiti GP, Alam N, Roy A, Roychoudhury S, et al. Alterations of ROBO1/DUTT1 and ROBO2 loci in early dysplastic lesions of head and neck: clinical and prognostic implications. *Hum Genet.* 2009 Mar;125(2):189-98.
119. Chia J, Cozzi SJ, Loh K, Bond C, Spring K, Leggett B, et al. Methylation of Thrombospondin-4 as a potential marker of colorectal cancer. *AACR Meeting; 2007; 2007.*
120. Du YY, Dai DQ, Yang Z. Role of RECK methylation in gastric cancer and its clinical significance. *World J Gastroenterol.* Feb 21;16(7):904-8.
121. Liu S, Ren S, Howell P, Fodstad O, Riker AI. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. *Pigment Cell Melanoma Res.* 2008 Oct;21(5):545-58.
122. Pesta M, Kulda V, Topolcan O, Safranek J, Vrzalova J, Cerny R, et al. Significance of methylation status and the expression of RECK mRNA in lung tissue of patients with NSCLC. *Anticancer Res.* 2009 Nov;29(11):4535-9.
123. Brait M, Begum S, Carvalho AL, Dasgupta S, Vettore AL, Czerniak B, et al. Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. *Cancer Epidemiol Biomarkers Prev.* 2008 Oct;17(10):2786-94.
124. Jin Z, Olaru A, Yang J, Sato F, Cheng Y, Kan T, et al. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. *Clin Cancer Res.* 2007 Nov 1;13(21):6293-300.
125. Adams L, Roth MJ, Abnet CC, Dawsey SP, Qiao YL, Wang GQ, et al. Promoter methylation in cytology specimens as an early detection marker for esophageal squamous dysplasia and early esophageal squamous cell carcinoma. *Cancer Prev Res (Phila Pa).* 2008 Oct;1(5):357-61.
126. De Jong WK, Verpooten GF, Kramer H, Louwagie J, Groen HJ. Promoter methylation primarily occurs in tumor cells of patients with non-small cell lung cancer. *Anticancer Res.* 2009 Jan;29(1):363-9.
127. Mokarram P, Kumar K, Brim H, Naghibalhossaini F, Saberi-firoozi M, Nouraiie M, et al. Distinct high-profile methylated genes in colorectal cancer. *PLoS One.* 2009;4(9):e7012.
128. Tong W, Kuang SQ, Wierda W, Keating MJ, Garcia-Manero G. Identification of Multiple Promoter Associated CpG Islands Commonly Methylated in Both Acute Lymphocytic Leukemia (ALL) and Chronic Lymphocytic Leukemia(CLL) Using Novel Genome-Wide Microarray Technique: Implications for Common Primordial Molecular Pathways in Lymphoid Leukemias. *ASH Annual Meeting 2008; 2008.*
129. Park do Y, Sakamoto H, Kirley SD, Ogino S, Kawasaki T, Kwon E, et al. The Cables gene on chromosome 18q is silenced by promoter hypermethylation and allelic loss in human colorectal cancer. *Am J Pathol.* 2007 Nov;171(5):1509-19.

130. Zhu W, Qin W, Hewett JE, Sauter ER. Quantitative evaluation of DNA hypermethylation in malignant and benign breast tissue and fluids. *Int J Cancer*. Jan 15;126(2):474-82.
131. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. *Cancer Cell*. 2002 Dec;2(6):485-95.
132. Luxen S, Belinsky SA, Knaus UG. Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer. *Cancer Res*. 2008 Feb 15;68(4):1037-45.
133. Rodriguez J, Munoz M, Vives L, Frangou CG, Groudine M, Peinado MA. Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer cells. *Proc Natl Acad Sci U S A*. 2008 Dec 16;105(50):19809-14.
134. Jansen RA, Liu JC, Liyanarachchi S, Crijns AP, Yan PS, Huang TH, et al. Prognostic impact of MAD1L1 promoter hypermethylation in advanced ovarian cancer. *ASCO Meeting 2006*; 2006.
135. Park JK, Ryu JK, Lee KH, Lee JK, Yoon WJ, Lee SH, et al. Quantitative analysis of NPTX2 hypermethylation is a promising molecular diagnostic marker for pancreatic cancer. *Pancreas*. 2007 Oct;35(3):e9-15.
136. Zheng H, Gao L, Feng Y, Yuan L, Zhao H, Cornelius LA. Down-regulation of Rap1GAP via promoter hypermethylation promotes melanoma cell proliferation, survival, and migration. *Cancer Res*. 2009 Jan 15;69(2):449-57.
137. Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, et al. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. *Cancer Res*. 2007 Dec 1;67(23):11335-43.
138. Watanabe T, Kobunai T, Toda E, Yamamoto Y, Kanazawa T, Kazama Y, et al. Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. *Cancer Res*. 2006 Oct 15;66(20):9804-8.
139. Yoshikawa H, Matsubara K, Zhou X, Okamura S, Kubo T, Murase Y, et al. WNT10B functional dualism: beta-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer. *Mol Biol Cell*. 2007 Nov;18(11):4292-303.
140. Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, et al. Silencing of bidirectional promoters by DNA methylation in tumorigenesis. *Cancer Res*. 2006 May 15;66(10):5077-84.
141. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. *Cancer Res*. 2006 Dec 15;66(24):11954-66.
142. Kanduri M, Cahill N, Goransson H, Enstrom C, Ryan F, Isaksson A, et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. *Blood*. Jan 14;115(2):296-305.
143. Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. *Cancer Res*. 2004 May 1;64(9):3014-21.
144. Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S, et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to

promoter hypermethylation of PTEN gene in gastric carcinoma. *Cancer Res.* 2009 Apr 1;69(7):2766-74.

145. Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T, et al. Epigenetic silencing of the PTEN gene in melanoma. *Cancer Res.* 2006 Jul 1;66(13):6546-52.

146. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. *Clin Cancer Res.* 2002 May;8(5):1178-84.

147. Rush LJ, Raval A, Funchain P, Johnson AJ, Smith L, Lucas DM, et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. *Cancer Res.* 2004 Apr 1;64(7):2424-33.

148. Gal-Yam EN, Egger G, Iniguez L, Holster H, Einarsson S, Zhang X, et al. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. *Proc Natl Acad Sci U S A.* 2008 Sep 2;105(35):12979-84.

149. Smith LT, Lin M, Brena RM, Lang JC, Schuller DE, Otterson GA, et al. Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. *Proc Natl Acad Sci U S A.* 2006 Jan 24;103(4):982-7.

150. Kim SK, Jang HR, Kim JH, Kim M, Noh SM, Song KS, et al. CpG methylation in exon 1 of transcription factor 4 increases with age in normal gastric mucosa and is associated with gene silencing in intestinal-type gastric cancers. *Carcinogenesis.* 2008 Aug;29(8):1623-31.

151. Fraga MF, Berdasco M, Ballestar E, Ropero S, Lopez-Nieva P, Lopez-Serra L, et al. Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies. *Cancer Res.* 2008 Jun 1;68(11):4116-22.

152. Friedrich MG, Weisenberger DJ, Cheng JC, Chandrasoma S, Siegmund KD, Gonzalgo ML, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. *Clin Cancer Res.* 2004 Nov 15;10(22):7457-65.

153. Murphy SK, Nolan CM, Huang Z, Kucera KS, Freking BA, Smith TP, et al. Callipyge mutation affects gene expression in cis: a potential role for chromatin structure. *Genome Res.* 2006 Mar;16(3):340-6.

154. Rose SL, Watts GS, Holtan N, Degeest K, Domann FE, Futscher BW. Epigenomic patterns in ovarian cancer. *AACR Meeting; 2006; 2006.*

155. Demokan S, Chang X, Chuang A, Brait M, Hoque M, Sidransky D, et al. Methylation of the KIF1A and EDNRB genes is a frequent event in head and neck cancer. *AACR Meeting; 2008; 2008.*

156. Ostrow KL, Park HL, Hoque MO, Kim MS, Liu J, Argani P, et al. Pharmacologic unmasking of epigenetically silenced genes in breast cancer. *Clin Cancer Res.* 2009 Feb 15;15(4):1184-91.

157. Jiang Y, O'Keefe CL, Dunbar A, Advani A, Sekeres MA, McDevitt MA, et al. High Throughput Methylation Arrays Allow for Identification of Complex Methylation Patterns in MDS. *ASH Annual Meeting 2007; 2007.*

158. Aytes A, Mollevi DG, Nadal M, Vidal A, Baixeras N, Guino E, et al. PI4K2 β and STIM2 are two new relevant genes for colorectal cancer. *AACR Meeting; 2008; 2008.*

159. Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, Nelson B, et al. Epigenetic silencing of novel tumor suppressors in malignant melanoma. *Cancer Res.* 2006 Dec 1;66(23):11187-93.

160. Tessema M, Belinsky SA. Mining the epigenome for methylated genes in lung cancer. *Proc Am Thorac Soc* 2008;5: 806-10.
161. Shin SH, Kim BH, Jang JJ, Suh KS, Kang GH. Identification of novel methylation markers in hepatocellular carcinoma using a methylation array. *J Korean Med Sci*;25: 1152-9.
162. Matsumura N, Huang Z, Mori S, et al. Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. *Genome Res*;21: 74-82.
163. Varley KE, Mitra RD. Bisulfite Patch PCR enables multiplexed sequencing of promoter methylation across cancer samples. *Genome Res*;20: 1279-87.
164. Serre D, Lee BH, Ting AH. MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome. *Nucleic Acids Res*;38: 391-9.